Table 1. miRs differentially expressed in spinal muscular atrophy (SMA), as reported in previous studies.
| hsa-miR | miRNome | Relative qPCR | Absolute qPCR* | Reference |
|---|---|---|---|---|
| miR-19a-3p | Upregulated | Upregulated | <10 molecules/µl serum; p=0.42 | Haramati et al., 2010; Gonçalves et al., 2018 |
| miR-23a-3p | Downregulated | Upregulated | 150–200 molecules/µl serum; 10 patients/controls analyzed; p=0.62 | Kaifer et al., 2019 |
| miR-206 | Nonsignificant | Upregulated | 50–100 molecules/µl serum; 15 patients/controls analyzed; p=0.24 | Valsecchi et al., 2015; Catapano et al., 2016; Bonanno et al., 2020 |
| miR-9 | Nonsignificant | Not tested | <10 molecules/µl serum; p=0.30 | Catapano et al., 2016 |
| miR-132 | Nonsignificant | Not tested | Not tested | Catapano et al., 2016 |
| miR-146a | Upregulated | Upregulated | <5 molecules/µl serum; p=0.10 | Sison et al., 2017 |
| 4miR-431 | Nonsignificant | Not tested | Not tested | Wertz et al., 2016 |
| miR-183 | Nonsignificant | Not tested | Not tested | Kye et al., 2014 |
*
p-Values refer to the significance of comparison of the miR levels in patients and controls by Mann–Whitney U-test. p-values < 0.05 were considered significant.